생체내 CRO 시장 보고서 : 유형별, GLP 유형별, 적응증별, 지역별(2026-2034년)

The global in-vivo CRO market size reached USD 5.7 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 10.1 Billion by 2034, exhibiting a growth rate (CAGR) of 6.49% during 2026-2034. The growing prevalence of chronic diseases worldwide and the increasing R&D expenditure by pharmaceutical companies are propelling the market growth.

IN-VIVO CRO MARKET ANALYSIS:

• Major Market Drivers: The rapid growth in the number of biotech startups and the rising focus on personalized and precision medicine are stimulating the market growth.
• Key Market Trends: Various outsourcing preclinical research studies and the inflating adoption of artificial intelligence in research methodologies are acting as growth-inducing factors.
• Competitive Landscape: Some of the prominent market companies include Biocytogen, Charles River Laboratories, Crown Bioscience, Eurofins Discovery, Evotec, Fortrea, Icon Plc, IQVIA Inc., Iris Pharma, Taconic Biosciences, Inc., and WuXi AppTec, among many others.
• Geographical Trends: North America dominates the market due to due to advanced healthcare infrastructure, strong pharmaceutical and biotechnology sectors, and high R&D investment.
• Challenges and Opportunities: The high costs and regulatory challenges hinder the market growth. However, adopting advanced technologies and streamlining compliance processes to enhance efficiency and reduce expenses will continue to propel the market growth over the foreseeable future.

IN-VIVO CRO MARKET TRENDS:

Increased Outsourcing by Pharmaceutical Companies

Pharmaceutical companies are focusing on outsourcing to in-vivo contract research organizations to enhance research efficiency and reduce costs. These CROs provide specialized expertise in animal studies, thereby enabling faster drug development and regulatory approval while allowing companies to focus on core competencies. For example, in July 2024, IntegriChain, delivering pharma's comprehensive data, consulting, technology, and outsourcing platform for data-driven commercialization, acquired Federal Compliance Solutions (FCS), a leading pharma advisory and managed services firm, to develop more profitable drug commercialization strategies. According to the in-vivo CRO market analysis report, this is acting as a growth-inducing factor.

Rise of Specialized CRO Services

The rise of specialized in-vivo CRO services reflects a growing demand for niche expertise in preclinical studies. These CROs offer tailored services in areas like animal modeling, pharmacokinetics, and toxicology, enhancing drug development efficiency and precision in therapeutic research and development, escalating the in-vivo CRO market demand. For instance, in June 2024, Lindus Health launched an all-in-one medical device CRO service, combining in-vivo CRO expertise with advanced technology and recruitment strategies, streamlining medical device clinical trials, accelerating participant enrollment across various therapeutic areas and regulatory pathways, etc.

Growing Focus on Drug Development

The increasing emphasis on drug development has led to greater support for in-vivo CRO. These organizations provide essential services for preclinical testing, enabling pharmaceutical companies to evaluate the safety and efficacy of new drugs in living organisms, speeding up the development process while reducing costs and resource requirements. For example, in May 2024, Cannovation Clinical Research Partners launched as a CRO specializing in cannabis-based drug trials, focusing on preclinical and clinical phases, developed cannabinoid-based therapeutics through collaborations with pharmaceutical companies, universities, and DEA researchers.

GLOBAL IN-VIVO CRO INDUSTRY SEGMENTATION:

Breakup by Type:

• Rodent
  • Rats
  • Mice
  • Others
• Non-Rodent

Rodent dominates the in-vivo CRO market share

Rodents, particularly mice and rats, dominate the market due to their genetic similarity to humans, cost-effectiveness, and rapid breeding. For example, mice are extensively used for cancer research and drug testing in preclinical trials. Moreover, companies, such as Envigo and Charles River Laboratories, developed advanced rodent models and enhanced services to support several stages of drug development.

Breakup by GLP Type:

• Non-GLP
  • In House
  • Outsourcing
• GLP Toxicology
  • In House
  • Outsourcing

GLP toxicology exhibits a clear dominance in the market

According to the in-vivo CRO market forecast report, GLP toxicology dominates the market, as companies strive to meet the growing demand for rigorous safety assessment in drug development. Advanced GLP toxicology services, including innovative study designs, specialized toxicology models, and enhanced data analytics platforms by leading organizations, like Covance and Labcorp Drug Development, are gaining traction.

Breakup by Indication:

• Autoimmune/Inflammation Conditions
  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Osteoarthritis
  • Irritable Bowel Syndrome
  • Others
• Pain Management
  • Chronic Pain
  • Acute Pain
• Oncology
  • Blood Cancer
  • Solid Tumor
  • Others
• CNS Conditions
  • Epilepsy
  • Parkinson's Disease
  • Huntington's Disease
  • Stroke
  • Traumatic Brain Injury
  • ALS
  • Muscle Regeneration
  • Others
• Diabetes
• Obesity

Oncology dominates the in-vivo CRO market outlook

Oncology dominates the market due to the high demand for cancer drug research and development. For example, CROs conduct animal studies to evaluate the efficacy and safety of new oncology therapies before clinical trials. Besides this, the rising innovations in supporting biotech and pharmaceutical companies to develop new cancer therapies are driving the segment's growth.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America dominates the market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

According to the in-vivo CRO market outlook report, North America leads the market due to its advanced healthcare infrastructure, substantial R&D investment, and presence of major pharmaceutical companies. The region benefits from a strong regulatory framework, experienced researchers, and high clinical trial activity. For instance, Charles River Laboratories, a key player in the U.S., provides comprehensive in-vivo services, from early-stage research to preclinical testing, which attracts global clients seeking high-quality, reliable research outcomes. This advantage positions North America as a dominant region.

COMPETITIVE LANDSCAPE:

The in-vivo CRO market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

• Biocytogen
• Charles River Laboratories
• Crown Bioscience
• Eurofins Discovery
• Evotec
• Fortrea
• Icon Plc
• IQVIA Inc.
• Iris Pharma
• Taconic Biosciences, Inc.
• WuXi AppTec

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global In-vivo CRO Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Rodent
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Rats
    • 6.1.2.2 Mice
    • 6.1.2.3 Others
  • 6.1.3 Market Forecast
• 6.2 Non-Rodent
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by GLP Type

• 7.1 Non-GLP
  • 7.1.1 Market Trends
  • 7.1.2 Key Segments
    • 7.1.2.1 In House
    • 7.1.2.2 Outsourcing
  • 7.1.3 Market Forecast
• 7.2 GLP Toxicology
  • 7.2.1 Market Trends
  • 7.2.2 Key Segments
    • 7.2.2.1 In House
    • 7.2.2.2 Outsourcing
  • 7.2.3 Market Forecast

8 Market Breakup by Indication

• 8.1 Autoimmune/Inflammation Conditions
  • 8.1.1 Market Trends
  • 8.1.2 Key Segments
    • 8.1.2.1 Rheumatoid Arthritis
    • 8.1.2.2 Multiple Sclerosis
    • 8.1.2.3 Osteoarthritis
    • 8.1.2.4 Irritable Bowel Syndrome
    • 8.1.2.5 Others
  • 8.1.3 Market Forecast
• 8.2 Pain Management
  • 8.2.1 Market Trends
  • 8.2.2 Key Segments
    • 8.2.2.1 Chronic Pain
    • 8.2.2.2 Acute Pain
  • 8.2.3 Market Forecast
• 8.3 Oncology
  • 8.3.1 Market Trends
  • 8.3.2 Key Segments
    • 8.3.2.1 Blood Cancer
    • 8.3.2.2 Solid Tumor
    • 8.3.2.3 Others
  • 8.3.3 Market Forecast
• 8.4 CNS Conditions
  • 8.4.1 Market Trends
  • 8.4.2 Key Segments
    • 8.4.2.1 Epilepsy
    • 8.4.2.2 Parkinson's Disease
    • 8.4.2.3 Huntington's Disease
    • 8.4.2.4 Stroke
    • 8.4.2.5 Traumatic Brain Injury
    • 8.4.2.6 ALS
    • 8.4.2.7 Muscle Regeneration
    • 8.4.2.8 Others
  • 8.4.3 Market Forecast
• 8.5 Diabetes
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Obesity
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast
• 8.7 Others
  • 8.7.1 Market Trends
  • 8.7.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Biocytogen
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Charles River Laboratories
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Crown Bioscience
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Eurofins Discovery
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Evotec
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Fortrea
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Icon Plc
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 IQVIA Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Iris Pharma
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
  • 14.3.10 Taconic Biosciences, Inc.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 WuXi AppTec
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials